[1] Kakli H A and Riley T D. Allergic Rhinitis. Prim Care. 2016;43(3):465-475.
[2] Klimek L, Sperl A, Becker S, et al. Current therapeutical strategies for allergic rhinitis. Expert Opin Pharmacother. 2019;20(1):83-89.
[3] Eifan A O and Durham S R. Pathogenesis of rhinitis. Clin Exp Allergy. 2016;46(9):1139-1151.
[4] Shen Y, Ke X, Yun L, et al. Decreased expression of interleukin37 and its antiinflammatory effect in allergic rhinitis. Mol Med Rep. 2018;17(1):1333-1339.
[5] Ignacio B J, Albin T J, Esser-Kahn A P, et al. Toll-like Receptor Agonist Conjugation: A Chemical Perspective. Bioconjug Chem. 2018;29(3):587-603.
[6] Zhang M, Liu L and Wang S. [Role of immune deviation by toll-liked receptor's doping LPS in pathogenesis of allergic rhinitis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014;49(4):288-293.
[7] Chi H, Li C, Zhao F S, et al. Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol. 2017;8:304.
[8] Greiff L, Ahlstrom-Emanuelsson C, Alenas M, et al. Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study. Inflamm Res. 2015;64(11):903-915.
[9] Tsitoura D, Ambery C, Price M, et al. Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015;98(4):369-380.
[10] Henmyr V, Carlberg D, Manderstedt E, et al. Genetic variation of the Toll-like receptors in a Swedish allergic rhinitis case population. BMC Med Genet. 2017;18(1):18.
[11] Kim S H, Kim S H, Chung S J, et al. Changes in basophil activation during immunotherapy with house dust mite and mugwort in patients with allergic rhinitis. Asia Pac Allergy. 2018;8(1):e6.
[12] Miyake K and Karasuyama H. Emerging roles of basophils in allergic inflammation. Allergol Int. 2017;66(3):382-391.
[13] Cassard L, Sperber K, Buivan T P, et al. Basophils from allergic patients are neither hyperresponsive to activation signals nor hyporesponsive to inhibition signals. J Allergy Clin Immunol. 2018;142(5):1548-1557.
[14] Arai T, Sakurai D, Iinuma T, et al. Basophils from allergic rhinitis patients show allergen-specific upregulation of thymic stromal lymphopoietin receptor. Ann Allergy Asthma Immunol. 2018;120(2):155-163.
[15] Chirumbolo S, Ortolani R and Vella A. CCR3 as a single selection marker compared to CD123/HLADR to isolate basophils in flow cytometry: some comments. Cytometry A. 2011;79(2):102-106.
[16] Hausmann O V, Gentinetta T, Fux M, et al. Robust expression of CCR3 as a single basophil selection marker in flow cytometry. Allergy. 2011;66(1):85-91.
[17] Lee J E, Ahn J C, Han D H, et al. Variability of offending allergens of allergic rhinitis according to age: optimization of skin prick test allergens. Allergy Asthma Immunol Res. 2014;6(1):47-54.
[18] Bousquet P J, Burbach G, Heinzerling L M, et al. GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy. 2009;64(11):1656-1662.
[19] Huang F L, Liao E C and Yu S J. House dust mite allergy: Its innate immune response and immunotherapy. Immunobiology. 2018;223(3):300-302.
[20] Lou H, Ma S, Zhao Y, et al. Sensitization patterns and minimum screening panels for aeroallergens in self-reported allergic rhinitis in China. Sci Rep. 2017;7(1):9286.
[21] Bousquet J, Schunemann H J, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70(11):1372-1392.
[22] Gardner L M, O'Hehir R E and Rolland J M. High dose allergen stimulation of T cells from house dust mite-allergic subjects induces expansion of IFN-gamma+ T Cells, apoptosis of CD4+IL-4+ T cells and T cell anergy. Int Arch Allergy Immunol. 2004;133(1):1-13.
[23] Ueda Y, Nakagome K, Kobayashi T, et al. Effects of beta2-adrenergic agonists on house dust mite-induced adhesion, superoxide anion generation, and degranulation of human eosinophils. Asia Pac Allergy. 2020;10(2):e15.
[24] He S, Zhang H, Chen H, et al. Expression and release of IL-29 by mast cells and modulation of mast cell behavior by IL-29. Allergy. 2010;65(10):1234-1241.
[25] Adlard A L, Dovedi S J, Telfer B A, et al. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer. 2014;135(4):820-829.
[26] Ethier C, Lacy P and Davoine F. Identification of human eosinophils in whole blood by flow cytometry. Methods Mol Biol. 2014;1178:81-92.
[27] Striz I, Pokorna H, Zheng L, et al. Different expression of integrins by mononuclear phagocytes in peripheral blood and bronchoalveolar lavage fluid. Respir Med. 1998;92(12):1326-1330.
[28] Lamkhioued B, Abdelilah S G, Hamid Q, et al. The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells. J Immunol. 2003;170(1):537-547.
[29] Greiff L, Cervin A, Ahlstrom-Emanuelsson C, et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012;13:53.
[30] Yin S C, Liao E C, Chiu C L, et al. Der p2 Internalization by Epithelium Synergistically Augments Toll-like Receptor-Mediated Proinflammatory Signaling. Allergy Asthma Immunol Res. 2015;7(4):393-403.
[31] Falcone F H, Haas H and Gibbs B F. The human basophil: a new appreciation of its role in immune responses. Blood. 2000;96(13):4028-4038.
[32] Koga-Yamakawa E, Murata M, Dovedi S J, et al. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice. Cancer Immunol Immunother. 2015;64(10):1229-1239.
[33] Kruger-Krasagakes S, Moller A, Kolde G, et al. Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol. 1996;106(1):75-79.
[34] Wu H, Qi H, Iwasaki D, et al. JNK-dependent NFATc1 pathway positively regulates IL-13 gene expression induced by (-)-epigallocatechin-3-gallate in human basophilic KU812 cells. Free Radic Biol Med. 2009;47(7):1028-1038.
[35] Gandhi N A, Bennett B L, Graham N M, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
[36] Thunberg S, Gafvelin G, Nord M, et al. Allergen provocation increases TH2-cytokines and FOXP3 expression in the asthmatic lung. Allergy. 2010;65(3):311-318.
[37] Takamatsu Y, Hasegawa M, Sato S, et al. IL-13 production by peripheral blood mononuclear cells from patients with atopic dermatitis. Dermatology. 1998;196(4):377-381.
[38] Lordan J L, Bucchieri F, Richter A, et al. Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells. J Immunol. 2002;169(1):407-414.